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SUMMARY 
 
Hepatic and intestinal endocrine cells are potentially helpful targets for 
recombinant insulin expression.  As the two cell types exhibit different secretion kinetics, 
it has been hypothesized that a combination of the two would better approximate insulin 
secretion kinetics from normal, functioning beta-cells than either cell type alone.  This 
hypothesis was tested using two hepatic cell lines transiently transduced with one of 
three adenoviruses for insulin expression along with a stably transfected recombinant 
intestinal L cell line.    
The insulin secretion kinetics were analyzed for both the hepatic and intestinal 
cells to determine the potential of combining them to reproduce the insulin secretion 
kinetics of a normal, functioning beta-cell.  It was observed that the two recombinant 
hepatic cell lines secreted insulin in a more sustained manner exhibiting slower release 
kinetics.  They also exhibited an increase in insulin secretion when stimulated by the 
cocktail of nutrient secretagogues (glucose and meat hydrolysate) versus stimulating 
with only glucose.  The cells transduced with the adenovirus containing an additional 
cytomegalovirus (CMV) promoter and green fluorescent protein (GFP) exhibited the 
highest insulin secretion after stimulation, whereas the cells transduced with an 
adenovirus encoding for destabilized preproinsulin mRNA exhibited the lowest secretion 
rates.   
The recombinant intestinal cell line (GLUTag-INS) secreted insulin with rapid 
kinetics upon stimulation, apparently due to the presence of secretory granules 
containing pre-synthesized insulin.    The experiments demonstrated that the cells 
stimulated with medium containing only meat hydrolysate exhibited a significantly higher 
insulin secretion relative to secretagogue-free controls.  The insulin secretion was not 
further enhanced when meat hydrolysate was combined with glucose.   
xii 
Overall, the results of this study indicate that a combination of these recombinant 
hepatic and intestinal cells would better approximate the biphasic kinetics of a normal, 
functioning beta cell.   
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CHAPTER 1 
INTRODUCTION 
 
Insulin-dependent diabetics lack the ability to regulate blood glucose levels.  This 
may be due to 1) an autoimmune attack on pancreatic beta-cells (as seen in type 1 
diabetes); or 2) an exhaustion of these insulin secreting cells (as seen in some late 
stages of type 2 diabetes).  Currently, no cures are available for insulin-dependent 
diabetes (IDD) and treatments have limitations including: limited ability to achieve 
glucose homeostasis with insulin injections or infusions; limited availability of donor 
organs; and immune rejection issues with cell and tissue-based therapies. 
A non-diabetic’s pancreatic beta-cells respond to a glucose stimulus by secreting 
insulin in a biphasic manner.  This method of control allows for rapidly lowering blood 
glucose during the first phase of insulin secretion followed by sustaining the lowered 
blood glucose over a period of hours during the second phase of insulin secretion.  
A combination of hepatic and intestinal cells has the potential to reproduce the 
physiologic regulation of blood glucose levels.  Our objective is to analyze insulin 
secretion kinetics of recombinant hepatic and intestinal cell lines and their ability to 
mimic those of beta-cells.   
Hepatic cells possess glucose sensing proteins, which aid in glucose homeostasis in 
the body. This sensory mechanism may be utilized via genetic engineering to facilitate 
insulin secretion with regulated release at the transcription level. Recombinant hepatic 
cells have been shown to reproduce the sustained, second phase of insulin secretion 
after exposure to a stimulus of glucose.   
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Enteroendocrine (EE) L cells respond to the ingestion of a meal by releasing their 
incretin peptide, glucagon like peptide-1 (GLP-1).  GLP-1 is released to potentiate 
glucose-induced insulin secretion, inhibit hepatic glucose production, and reduce 
appetite and food intake.  This regulated secretion may be targeted through genetic 
engineering so that insulin accumulates in the same secretory vesicles and is therefore 
released with the same kinetics as endogenous GLP-1.  Recombinant EE cells have 
demonstrated this ability to reproduce the acute and transient first phase of insulin 
secretion.   
An intrinsic and closed loop method for achieving glucose homeostasis is the “holy 
grail” of blood glucose control.  We will be analyzing the insulin secretion kinetics of 
hepatic and intestinal cell lines for their potential to provide this crucial regulation.   
3 
CHAPTER 2 
BACKGROUND 
 
 
2.1 Insulin-Dependent Diabetes  
As a consequence of having no functional pancreatic beta-cells, insulin 
dependent diabetes (IDD) patients are unable to regulate blood glucose concentrations.  
IDD is an insulin deficiency caused by either 1) a genetically determined autoimmune 
disease, which destroys the insulin producing beta-cells of the pancreas (type 1 
diabetes); or 2) insulin resistance and degeneration of the beta-cells due to chronically 
high insulin levels (type 2 diabetes).  
The number of affected people is increasing worldwide. According to the Center 
for Disease Control (CDC), diabetes was the sixth leading cause of death in the United 
States in 2004.  As of 2005, 20.8 million people in the United States have diabetes which 
is 7.0% of the population (<diabetes.org> 2006).  Approximately 4 million of these 
people have IDD.   
Many IDD patients must endure multiple daily injections of insulin to roughly 
maintain physiological levels of blood glucose.  Even with insulin injections, the resulting 
fluctuations in blood glucose concentrations have severe medical implications such as 
retinopathy, heart disease and neuropathy.  The tight control of these fluctuations can 
prevent or at least postpone dangerous long-term complications.  (Chan, Fujimiya et al. 
2003)  
A treatment is needed to improve glycemic control, prevent severe hypoglycemia 
and improve quality of life. 
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2.2 Current Treatments 
Currently no cures exist for diabetes, only limited treatment options.  Current 
treatments for IDD include insulin injections, insulin pumps, whole pancreas 
transplantations or pancreatic islet transplantations (Bottino et al. 2003).  These 
treatments have severe limitations including: limited availability of donor organs, immune 
rejection issues, and limited glucose regulation.   
Insulin injections require IDD patients to manually monitor their blood glucose 
levels by sampling blood vi multiple daily finger sticks and administer multiple daily 
injections of precisely calculated amounts of insulin.  This method has limited ability to 
prevent glycemic excursions and requires a high degree of patient compliance. It also 
does not reproduce natural insulin secretion dynamics of a normal, functioning pancreas 
seen in Figure 1 (Rorsman, Eliasson et al. 2000; Chan, Fujimiya et al. 2003).   
In a healthy person, the pancreas releases insulin in two distinct phases (Figure 
1).  The first phase is a burst of insulin which begins within minutes of ingesting a meal 
and continues 30 to 60 minutes after rapidly lowering blood glucose levels in the 
patients.  The second phase is a slower and sustained insulin release causing prolonged 
insulin secretion 1 to 3 hours after eating a meal; maintaining the blood glucose level in 
the patient (Reimann and Gribble 2002; Reimann, Ward et al. 2006). 
Another current treatment is the insulin pump, which allows more frequent dosing 
and better controlled insulin administration.  This device also has limited ability to 
prevent glycemic excursions as it neither automatically measures blood glucose levels 
nor calculates the appropriate amount of insulin to administer; therefore, this is not a 
closed loop system.  The Medtronic Minimed real-time glucose monitoring system is one 
step closer to a closed loop system as it incorporates a continuous glucose monitor and 
an insulin pump, but it still requires finger sticks and user instructions for dispensing 
insulin (Medtronic.com).  Insulin pumps are also limited by issues with infections at the 
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implantation site and their bulkiness of the devices (Schaepelynck-Belicar, Dufaitre-
Patouraux et al. 2005).  No closed loop devices are currently available and no 
continuous blood glucose monitoring devices are approved to completely replace 
traditional monitoring methods.  
 
 
Figure 1: Insulin secretion from healthy patients.  Insulin release in a healthy patient 
exhibits two phases of insulin secretion to regulate blood glucose levels and limit 
excursions.  The first phase is a burst of insulin followed by the second phase containing 
more sustaining insulin release.  Adapted from (Rorsman, Eliasson et al. 2000). 
 
 
2.3 Sources of Beta-Cells 
 
2.3.1 Islet Transplantation 
 The glucose-responsive and insulin secreting beta-cells are found in the islets of 
Langerhans in the pancreas.  These spheroid structures contain specialized cells  
(alpha-, beta-, delta- and PP-cells) which produce and secrete hormones necessary for 
glycemic control (glucagon, insulin, somatostatin, and pancreatic polypeptide, 
respectively).  Islets exist as “mini-organs” with highly organized cell clusters.  Islets are 
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a potential treatment for IDD and may be transplanted into IDD patients as a whole-
organ graft of the pancreas or as isolated islets.   
One limitation with this islet transplantation is the number of donors.  
Approximately 6000 human pancreata are available each year in the United States with 
only half considered suitable quality for transplantation.  Islets of 2-4 donors are required 
to treat an IDD patient with 2-4 implantations required as islets from each donor become 
available (Chan, Fujimiya et al. 2003; Xu, Li et al. 2003b; Wiseman and Gill 2005; 
O'Connell P, Hawthorne et al. 2006).  Therefore, less than 1000 patients per year may 
be treated with this method— amounting to less than 0.1% of type 1 diabetics (Rother 
and Harlan 2004).  
 Shapiro et al studied IDD patients receiving islet transplantations in an 
international, multicenter trial of the Edmonton protocol, developed by physicians at the 
University of Alberta in Edmonton using donor pancreata transplants along with a 
steroid-free immunosuppression regimen (Shapiro, Ricordi et al. 2006).  Islet 
transplantations exhibit varied results when treating IDD.  Out of the 36 subjects in the 
study, 58% exhibited insulin independence (Figure 2).   Out of the IDD patients gaining 
insulin independence, 76% of the subjects were reverted to insulin dependence 2 years 
after transplantation (Shapiro, Ricordi et al. 2006).  Patients receiving the transplant also 
exhibited deficient first phase insulin secretion and delayed insulin secretion after an oral 
glucose load.   
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Figure 2: Results of international trial of the Edmonton protocol.  76% of subjects 
receiving islet transplantations reverted to insulin dependence within 2 years of 
transplantation.  The bars represent a 95% confidence interval at these time points.  
Image adapted from (Shapiro, Ricordi et al. 2006). 
 
Efforts to expand islet cellular mass and to locate an alternate source for islets 
are being pursued.  The expansion of islet cellular mass has resulted in reduced insulin 
production after in vitro culturing of the cells.  Xenogeneic sources, particularly porcine 
islets, may be a possible means to alleviate cell sourcing issues, as pigs expand into 
large litters and islets may be used from either neonatal or adult sources.  They also 
produce an insulin form similar to humans.  In fact, porcine insulin has been used to treat 
IDD patients for over 60 years (Rother and Harlan 2004).  Concerns regarding a 
xenogeneic tissue source such as cross-species transmission of a pig retrovirus and 
need for immunosuppressive drugs limit the success of the technology.   
Regardless of whether the source is an allo- or xenogeneic donor, chronic 
immunosuppression is necessary for islet transplantation.  These immunosuppresive 
drugs result in side effects which some patients consider worse than living with IDD.  
The immune suppressing drugs also have a negative impact on the transplanted islets.  
They have been shown to destroy implanted islets, decrease beta-cell function, and to 
elicit an innate immune response.  Other side effects include mouth ulcers, deteriorating 
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renal function, diarrhea, fatigue and hypertension (Shapiro, Ricordi et al. 2006).  These 
side effects only exacerbate the secondary complications common to IDD.  It is even 
possible that the use of these drugs actually increases patient mortality (Rother and 
Harlan 2004).   
 
2.3.2 Continuous Beta-Cell Lines 
 An alternative cell source for treating IDD is transformed beta-cell lines.  Cell 
lines have been developed by expressing oncoprotein transgenes in rodent beta-cells 
including βTC-tet and βTC3 (Efrat 2004).  Cell lines offer the benefits of being well-
defined, able to maintain differentiated properties for up to 50 passages, and are easily 
expanded into large cultures. Drawbacks of using cell lines as an IDD treatment include 
hypersensitivity to sub-physiologic glucose concentrations and the fear of adverse 
reactions from implanting a transformed cell line (Papas, Long et al. 1996; Efrat 2004).    
An engineered cell with the ability to maintain long-term glucose-responsiveness has yet 
to be developed (Sambanis 2000).   
 
2.3.3 Differentiating Stem Cells into Pancreatic Beta-Cells 
Another cell based therapy currently being studied is the use of stem cells 
differentiated into pancreatic beta-cells.  Differentiation of embryonic stem (ES) cells 
remains a challenge.  According to a review article by Rivas-Carrillo et al, successful 
derivations of ES cells into islet-cells is more difficult than initially expected (2007).  More 
information on the mechanisms driving the development of the pancreas is needed to 
successfully produce these cells (Rivas-Carrillo, Okitsu et al. 2007).  ES cells are 
typically allogeneic or xenogeneic; therefore, they are also expected to be immunogenic.  
The current ES cell lines are not a feasible treatment for diabetes.  These cells were 
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determined to be contaminated with a mouse protein from mouse feeder layers used for 
culturing the ES cell lines (Kuleshova, Gouk et al. 2007).   
Adult progenitor cells have also been studied to determine their potential to 
differentiate into insulin-secreting cells.  Progenitor cells have been investigated from a 
variety of sources including the pancreatic ducts, exocrine pancreas, pancreatic islets, 
liver, spleen, and bone marrow.  At this time, some of these cell types have 
demonstrated the ability to maintain normoglycemia in animals (Lock and Tzanakakis 
2007).  Though, an additional concern is that the immune system will continue to 
recognize and destroy these cells after they differentiate into beta-cells due to the 
presence of the genetic disease in type 1 diabetes (Xu, Li et al. 2003b; Fujimoto, Sasaki 
et al. 2005; Han, Lee et al. 2007).   
  
2.3.4 Engineered Non-Beta-Cells 
Non-beta-cells cells offer a promising cell source for the development of 
personalized medicine to treat diabetes.  These are potentially autologous cells which 
could relieve the cell sourcing and immune acceptance issues.  They offer an alternate 
blood glucose management system creating a closed loop system to monitor blood 
glucose and secrete appropriate amounts of insulin.  They do not express beta-cell 
antigens allowing these cells to avoid an attack by the immune system, as seen in type 1 
diabetes (Han, Lee et al. 2007).   
 Various non-beta cells are being researched including enteroendocrine (EE), 
hepatic, skeletal, neuroendocrine, and adipocytes.   Preadipocytes have been 
engineered to secrete furin compatible insulin, but the lack of glucose sensitivity 
prevents normalization and stabilization of glucose (Fujimoto, Sasaki et al. 2005; Ito, 
Bujo et al. 2005).  Ito et al expressed furin-cleavable insulin in primary adipocytes and 
transplanted the cells into diabetic mice (Ito, Bujo et al. 2005).  The cells normalized the 
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blood glucose levels, but the researchers failed to mention the effect of cell number on 
hypoglycemia and the kinetics of insulin release (Ito, Bujo et al. 2005; Wideman, Fujita et 
al. 2007).  
Another cell source, skeletal muscle was injected with two adeno-associated 
viruses (AAVs)—one with furin-cleavable proinsulin and one with glucokinase.  IDD was 
reversed in streptozotocin (STZ) mice injected with these AAVs, but normoglycemia was 
not maintained.  This demonstrated the need for glucose-responsive insulin secretion 
(Wideman, fujita et al. 2007).   
 
2.3.4.1 Hepatic Cells 
One promising cell source for autologous cell therapy are hepatic cells which 
express glucose sensing components similar to pancreatic beta-cells (Xu, Li et al. 
2003b). An analogous glucose-sensing component is present in liver and beta-cells—
glucose transporter type 2 (GLUT2). Auricchio et al consider, GLUT2 and glucokinase 
“…essential factors for glucose metabolism” (Auricchio, Gao et al. 2002).  Once glucose 
enters the cells via the GLUT2 transporter it is phosphorylated by glucokinase.  This is 
considered the rate limiting step enabling the sensing of extracellular glucose 
concentration in liver cells; making these cells a potential source of non-beta cells for 
treating IDD (Reimann and Gribble 2002; Efrat 2004; Klover and Mooney 2004).   
 
2.3.4.1.1 Recombinant Hepatic Cell Lines 
Primary hepatic cells are candidates for genetic engineering due to their low cell 
turn over rate, high regenerative capacity, and ability to sense glucose concentration 
fluctuations.  This response to glucose may be targeted via genetic engineering to 
develop insulin secreting and glucose-responsive cells.  These cells offer a potential in 
vivo therapy for treating diabetes.   
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To aid in studying the potential of the hepatic cells to treat IDD, recombinant 
hepatic cell lines have been developed by modifying rat and human hepatoma cell lines, 
(H4IIE and HepG2 cells respectively). Although, hepatic cells do not possess the 
capacity for regulated secretion, transcriptional regulation of insulin biosynthesis is 
incorporated into these cell lines using promoters which are responsive to glucose 
concentrations.  This transcriptional regulation is slower and more sustained simulating 
the second phase of insulin secretion from a beta-cell as seen previously in Figure 1.  
Recombinant hepatic cells are unable to provide the acute first phase of insulin secretion 
as seen in beta-cells (Ito, Bujo et al. 2005; Wideman, fujita et al. 2007); therefore, 
requiring the combination with an additional cell type to reproduce the biphasic kinetics 
of the beta-cells.   
 
2.3.4.1.2 Furin Compatible Insulin for Hepatic Cell Lines 
Hepatic cells do not contain the endoproteases required to process proinsulin 
into insulin—prohormone convertases PC1/3 and PC2— as seen in beta-cells. To 
alleviate this problem, a mutated proinsulin that is cleavable by furin, a ubiquitous 
protease, can be incorporated into the transgene (Wideman, fujita et al. 2007).  The 
furin-compatible transgene allows cleavage of C-peptide from the A and B chains of 
insulin to activate the insulin.  Furin modified human insulin cDNA has been shown to 
lower blood glucose levels in diabetic animals (Short, Okada et al. 1998; Thule and Liu 
2000; Shifrin, Auricchio et al. 2001; Auricchio, Gao et al. 2002). Release of C-peptide 
also has an added benefit in treating diabetes.  When C-peptide was injected into 
patients demonstrating early signs of diabetic neuropathy, it improved blood vessels and 
nerves in diabetic patients (Sadrzadeh, Glembourtt et al. 2007).  
Transgenes with glucose-responsiveness and furin compatibility have been 
created by Thulé et al (Veterans Administration Medical Center, Atlanta, GA) (Figure 3).  
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These transgenes respond to glucose stimulations through transcriptional regulation of 
the promoter (Thule, Liu et al. 2000). They have three promoter elements from hepatic 
cells (referred to as G3) which exploit the cells’ glucose sensitivity and responsiveness.  
The transgenes also include a furin compatible human insulin cDNA (2xfur).  Diabetic 
rats injected with an adenovirus containing the G3-2xfur insulin transgene (Figure 3A) 
maintained normoglycemia (Thule and Liu 2000; Thule, Campbell et al. 2006).  
According to Thulé and Liu, they “demonstrated the feasibility of utilizing transcription to 
control transgenic insulin production in a rodent model of diabetes mellitus” (2000).  This 
transgene exhibited many of the necessary characteristics for lowering blood glucose 
and has also been combined with a cytomegalovirus (CMV) promoter for green 
fluorescent protein (GFP) allowing visualization of the transduction.  The genetic 
engineering of hepatic cells requires 1) a vector for genetically engineering the cells 
such as adenovirus transduction and 2) modifications to the insulin enabling processing 
of the prohormone.   
 
 
 
 
 
 
Figure 3: Transgenes for adenovirus transduction. These vectors were developed by 
Thulé et al: A) G3-2xfur containing the G3 promoter, engineered PPI mRNA and a 
poly(A) tail B) G3-InsTail containing the G3 promoter, three copies of the 2xfur PPI and a 
poly(A) tail C) G3-Track containing the G3-2xfur and the cytomegalovirus (CMV) 
promoter for green fluorescent protein (GFP). 
 
2xfur CMV GFP 
2xfur poly(A)
2xfur 2xfur poly(A)2xfur 
A) 
 
 
 
 
B) 
 
 
C) 
G3 promoter
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2.3.4.1.3 Nonsense-Mediated mRNA Decay (NMD)  
The transcriptional expression of insulin in recombinant hepatic cells may be 
further regulated by incorporating engineered PPI mRNA with enhanced down-regulation 
secretion of insulin (Figure 3C).  Tang and Sambanis demonstrated that “the prolonged 
stability of PPI (PPI) mRNA causes the sluggishness of secretion down-
regulation…resulting in the secretion of insulin long after the stimulus was removed” 
(Tang and Sambanis 2003b).  The inability of the recombinant cells to rapidly down-
regulate insulin secretion may result in hypoglycemic episodes.  This was demonstrated 
in vitro by Tang and Sambanis who compared the engineered PPI mRNA (InsTail) with a 
control PPI mRNA in vitro (2003b).  The expedited decay of the engineered PPI mRNA 
allows for faster elimination of the mRNA, which may prevent hypoglycemia in animal 
models.   In the experiment by Tang and Sambanis (2003b), the control and InsTail 
vectors were responsive to tetracycline (tet) due to presence of the tet regulated 
promoter.  When the cells were exposed to doxycycline (DOX), a tet isomer, the process 
of transcription was stimulated; resolving the up- and down-regulation kinetics for the 
two vectors.   The InsTail vector exhibited faster kinetics in down regulation of 
engineered PPI mRNA and consequently insulin secretion after exposure to DOX 
(Figure 4).  As predicted, the control vector did not experience a significant down-or up-
regulation of insulin expression.   
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Figure 4: Down-regulation of destabilized insulin.  The transcription of engineered 
PPI mRNA (InsTail) (filled squares) and control PPI mRNA (open circles) were 
stimulated by a doxycycline (DOX) square wave (Tang and Sambanis 2003b). 
 
 
Thulé et al have exploited this enhanced down-regulation kinetics by modifying 
the G3-2xfur transgene to express the engineered PPI mRNA (G3-InsTail) (Figure 3B).  
The G3-2xfur was also modified in a separate vector by adding a cytomegalovirus 
promoter (CMV promoter) controlling expression of green fluorescent protein (GFP) (G3-
Track) (Figure 3C).  These three vectors allow for analysis and comparison of insulin 
secretion kinetics.  Additionally, G3-Track allows an assessment of the transduction 
efficiency through examining cells with fluorescent microscopy. 
 
2.3.4.1.4 Adenovirus Transduction 
An adenovirus transduction may be used to genetically engineer the hepatic cells 
for glucose responsive insulin secretion.  Recombinant adenoviruses are non-enveloped 
DNA viruses which are replication deficient due to the deletion of the E1 and E4 viral 
genes.  Adenoviruses are able to efficiently transduce both proliferating and quiescent 
cells.  High titres may be generated with this virus on the order of 1010 to 1011 PFU/mL.  
They package large genes up to 8kb and have a broad tropism.  They do not integrate 
into the genome, therefore, preventing insertion into an oncogene as seen in 
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retroviruses (Ritter, Lehmann et al. 2002)  Adenoviruses have some limitations in vivo 
including the elicitation of an immune response which may require immunosuppressive 
drug treatment and result in loss of expression over time due to the transient expression 
of the virus.  Strategies for circumventing the immune response issues including 
monoclonal antibody therapy and neutralization of proinflammatory cytokines.  Overall, 
adenoviruses are a good candidate for in vitro gene therapy studies especially the 
transduction of hepatic cells, but are limited for in vivo applications. 
 
2.3.4.2 Enteroendocrine (EE) Cells 
Another promising cell source for autologous cell therapy are the EE cells. EE 
cells are responsible for 60% of the glucose dependent insulin secretion following an 
oral glucose load (Theodorakis, Carlson et al. 2006).  L and K cells, two types of EE 
cells, have been confirmed to express the same glucose sensor, glucokinase, as found 
in beta cells (Theodorakis, Carlson et al. 2006).  Gastric inhibitory polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) are two glucose-dependent incretins secreted by the K 
and L cells, respectively, in response to food intake.   
L cells and K cells are located in the gut, enabling direct nutrient contact.  K cells 
are located in the duodenum.  The exact location of L cells is under debate, but most are 
limited to the region between the ileum and colon (Reimann, Maziarz et al. 2005).  The 
location of both of these EE cells in the gut supports the observation that GLP-1 
secretion exhibits similar kinetics as GIP as shown in Figure 5 (Schirra, Katschinski et al. 
1996; Theodorakis, Carlson et al. 2006).  In healthy subjects, GLP-1 aids in maintaining 
blood glucose homeostasis by enhancing insulin secretion of beta-cells in a glucose 
dependent manner.  GLP-1 secretion is stimulated by an oral administration of 
carbohydrates, lipids and amino acids (Reimer, Darimont et al. 2001).  In contrast, GIP is 
not effective in stimulating insulin secretion (D'Alessio and Vahl 2004).  GLP-1 has been 
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demonstrated to increase insulin release and promote glucose homeostasis; even 
correcting hyperglycemia in type 2 diabetic subjects (D'Alessio and Vahl 2004).   It is 
also known to 1) stimulate the proliferation and neogenesis of beta-cells; 2) decrease 
appetite; 3) decrease gastric emptying and acid secretion in the stomach; and 4) 
decrease glucagon production in patients (Wideman, Yu et al. 2006).   GLP-1 is being 
studied (Reimann and Gribble 2002) and mimetic drugs (Byetta) are being marketed to 
treat type 2 diabetics.  Though, its major limitation is the 1-2 minute half-life of GLP-1 
(D'Alessio and Vahl 2004), which Byetta circumvents by implementing a mimetic drug 
(approved for type 2 diabetics only).   
 
  
Figure 5: Response ton oral glucose ingestion.  The release of A) insulin B) glucagon 
like peptide-1 (GLP-1) and C) gastric inhibitory peptide (GIP)  are stimulated by an 
increase in the plasma glucose concentration.  The oral ingestion of glucose ranged 
from 50 to 100 grams.  Image adapted from (Schirra, Katschinski et al. 1996). 
 
A) 
B) C) 
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L cells naturally release GLP-1 from secretory vesicles in response to nutrient 
stimulation.  The acute response exhibited by GLP-1 is due to its release from secretory 
vesicles in response to nutrient ingestion.  The release of GLP-1 mimics the acute and 
transient first phase of beta-cell insulin secretion (Schirra, Katschinski et al. 1996)—the 
phase not reproduced by recombinant hepatic cells.  This innate glucose-
responsiveness can be targeted through genetic engineering to express insulin.  EE 
cells offer a promising ancillary system for treating diabetes when combined with a cell 
type capable of producing a second phase release of insulin such as hepatic cells.   
A pure population of primary L cells would be the ideal culture to study the 
response of GLP-1 to a secretagogue.  Unfortunately, cells isolated from the intestinal 
epithelium constitute a mixed population which, currently, cannot be separated into a 
single-cell type.  The isolated cells typically contain only 10-30% L cells (Reimann and 
Gribble 2002; Reimann, Ward et al. 2006). Therefore, the purification of a primary cell 
population to a single-cell type is not possible at this time.  A solution to this problem is 
EE cell lines, which provide a homogeneous population for these studies.   
 
2.3.4.2.1 L cell line: NCI-H716 
After transducing an L cell line (human NCI-H716 cells) with an adeno-
associated virus (AAV) containing an insulin gene, the recombinant cells (rNCI-H716) 
responded to secretagogue stimulations by secreting insulin with the same kinetics as 
their release of GLP-1 (Figure 6).  The engineered EE cell line responded acutely 
simulating the first phase of insulin secretion from a beta cell.  This system could 
potentially eliminate the glycemic excursions in the blood when combined with a cell 
releasing insulin in a sustained manner; providing a more physiological condition for the 
patient.   
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Figure 6: Response of a recombinant L cell line to a nutrient stimulation.  NCI-
H716 cells were transduced with an adeno-associated virus (AAV) containing insulin and 
enhanced green fluorescent protein (EGFP).  The rNCI-H716 cells experienced a 2.7 
fold increase in insulin secretion after stimulation with meat hydrolysate (a nutrient 
secretagogue).  The secretion dynamics mimicked the 4.2 fold increase in glucagon like 
peptide-1 (GLP-1) after the same stimulation with meat hydrolysate.   
The graphs are adapted from (Tang and Sambanis 2003a). 
 
 It has been demonstrated that NCI-H716 genetically engineered to express 
insulin will accumulate insulin in the same secretory granules used to store GLP-1 (Tang 
and Sambanis 2003a).  The cells are co-localize insulin and GLP-1 in the same 
secretory granules and the contents of the granules are released upon stimulation with a 
nutrient secretagogue; therefore, experiencing similar secretion kinetics.   
This cell line was not used in the experiments included in this thesis, but it does 
exemplify the insulin secretion kinetics of recombinant L cells.   
 
2.3.4.2.2 L cell line: GLUTag 
A transgenic mouse L cell line (GLUTag) was developed to study the signaling 
pathways responsible for the release of GLP-1 in response to physiologic stimuli.  This 
cell line is a homogenous population of L cells and contains the proglucagon promoter 
Insulin Secretion Rate 
(Normalized to basal) 
GLP-1 Secretion Rate 
(Normalized to basal) 
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controlling the SV40 large T antigen (Reimann, Maziarz et al. 2005).  As seen with NCI-
H716 cells, GLUTag cells should also express the prohormone convertases, PC 1/3 and 
PC 2, required to process proglucagon into glucagon releasing the GLP-1 molecule.  
These are also the same endoproteases required to process proinsulin into insulin.  
Therefore, the GLUTag cells do not require the furin mutated PPI cDNA to allow for 
proteolytic processing.    
To analyze insulin secretion from this glucose-responsive cell line, recombinant 
GLUTag cells were developed in the Sambanis lab by Heather Bara.  The human B10 
mutated insulin gene was stably transfected into GLUTag cells.  The gene was 
expressed along with neomycin resistance allowing for selection of a stable clone 
(Figure 7).  The most robust insulin secreting colony was selected for this study and 
named GLUTag-INS (Bara 2007).  These cells were demonstrated to express both PC 
1/3 and PC 2 prohormone convertases (Bara and Sambanis, in preparation). 
 
 
Figure 7: Plasmid used for generation of the stable GLUTag clone (GLUTag-INS).  
The plasmid contains the cytomegalovirus promoter (CMV), human B10 modified PPI 
(hB10 Insulin), SV40 promoter (SV40) and neomycin resistance (Rneo).  Diagram 
obtained from Heather Bara. 
 
2.3.4.2.3 K cell line 
Another EE cell type, K cells, has been targeted by Cheung et al and Han et al 
for glucose-responsive insulin secretion (Cheung, Dayanandan et al. 2000; Han, Lee et 
al. 2007).   Han et al created a stable insulin secreting clone from STC-1 cells (a mixed 
population of mouse EE cells).  These cells were implanted into diabetic mice and 
restored normoglycemia within 2 weeks of implantation.  Normoglycemia was 
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maintained for 2 to 3 weeks post-implantation after which mice became hypoglycemic 
(Han, Lee et al. 2007).   
 
2.4 Combination Approach 
Recombinant hepatic and recombinant EE cells have been demonstrated to have 
differing insulin secretion dynamics.  Recombinant hepatic cells better approximate the 
slower and more sustained second phase of insulin secretion from a beta-cell while the 
recombinant EE cells approximate the acute first phase of insulin secretion.  Neither cell 
type alone could reproduce the secretory dynamics of a normal, functioning beta-cell.  A 
combination of hepatic and EE cells is proposed to mimic the biphasic response of a 
functioning beta cell.  It should more accurately reproduce beta-cell kinetics than with 
either cell type alone.   
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1: Cell Culture and Transduction 
 
3.1.1 Recombinant Intestinal Cell Line: GLUTag-INS 
GLUTag-INS were developed by Heather Bara in the Sambanis lab (Georgia 
Institute of Technology, Atlanta, GA) by stable transfection of GLUTag cells obtained 
from Dr. Brubaker (University of Toronto, Toronto, Canada) with the permission of Dr. 
Drucker (University of Toronto, Toronto, Canada).  The transgene for stable insulin 
expression was constructed by Heather Bara who inserted the human B10 mutated 
insulin gene (Genentech, San Francisco, CA) into the EcoRI site of the pcDNA3.1(+) 
vector (Invitrogen, Carlsbad, CA) (Figure 7).  Selection of a stable clone was facilitated 
by the Geneticin resistance of the vector.   
The GLUTag-INS cells were grown in culture medium (Dulbecco’s Modified 
Eagle’s Medium (DMEM, Sigma) supplemented with 10% Fetal Bovine Serum (FBS, 
Sigma), and 1% penicillin/streptomycin (pen/strep, Sigma) in a humidified incubator at 
37oC and 5% CO2.  They were split at a ratio of 1:5 at approximately 80% confluency.   
 
3.1.2 Recombinant Hepatic Cell Lines: rHepG2 and rH4IIE  
HepG2 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and were propagated in culture medium (Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% FBS, and 1% pen/strep) in a humidified 
incubator at 37oC and 5% CO2.  Culture flasks were coated with 0.4mg/mL PureCol 
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collagen (Inamed Biomaterials, Fremont, CA).  The cells were split at a ratio of 1:6 at 
approximately 80% confluency.    
H4IIE cells were obtained from the ATCC (Manassas, VA).  The cells were 
propagated in culture medium (DMEM supplemented with 10% FBS, and 1% pen/strep) 
in a humidified incubator at 37oC and 5% CO2. They were split at a ratio of 1:10 at 
approximately 80% confluency 
To produce recombinant HepG2 (rHepG2) and recombinant H4IIE (rH4IIE) cells, 
cells were transduced with either AdG3-InsTail, AdG3-Track or AdG3-2xfur (described in 
further detail in section 3.2.2), obtained from the laboratory of Dr. Peter Thulé (VA 
Hospital, Atlanta, GA).  The adenoviruses incorporated the vectors described in Figure 
3.  The AdG3-InsTail virus contained three copies of the glucose sensitive promoter 
GlRE (G3) and furin compatible human insulin (2xfur) which was modified to enhance 
destabilization.  The AdG3-2xfur virus contained the G3 promoter and furin compatible 
human insulin (2xfur).  The AdG3-Track virus contained the G3-2xfur vector with an 
additional CMV promoter for GFP (Figure 3).   
 
3.2 Secretion Studies 
 
3.2.1 Intestinal Cell Line 
Cells were plated on day -1 at a concentration of 1x106 cells per well of a 6 well 
plate containing 2mL culture medium.  The numbering convention for experimental days 
was based on the hepatic cells.  The intestinal cells were not altered on day 0.  Medium 
was changed on day 1 to BASAL medium (DMEM containing 5mM glucose (Sigma), 
1x10-7M Dexamethosone (DEX, Sigma), 2% FBS, 1% pen/strep.  Samples were taken at 
0, 12 and 24 hours after medium change on day 1.   
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On day 2 (24 hours after 0 hour sample), the medium was changed to either MH 
only stimulation (MH) medium [DMEM containing, 2% protein hydrolysate from meat 
(MH/peptone, Sigma), 10-7M DEX, 2% FBS, 1% pen/strep], cocktail medium (cocktail) 
(DMEM containing 20mM glucose, 2% MH, 10-7M DEX, 2% FBS, 1% pen/strep) or basal 
medium. Samples were taken at 24, 26, 28, 36 and 48 hours.   
Insulin accumulation was calculated for each of the time points.  It was assumed 
that the wells contained 0mM of insulin immediately after a change in medium.  A total of 
four independent experiments (each containing 2 sampled wells) were averaged and the 
standard deviation and standard error between the experiments were calculated.  A 
Grubb’s T test was performed to determine the existence of outliers.  The calculations 
showed that the experiment from 12/08/07 was an outlier for almost every well.  
Because of this statistical determination, the entire experiment was removed from the 
calculations.  Hence, reported results are the averages of three independent 
experiments each containing 2 sampled wells.   A complete listing of the data points may 
be found in Appendix A.   
Insulin secretion rate (ISR) was calculated by determining the differential 
secreted insulin secretion between two time points and dividing this insulin amount by 
the time difference between the two points.  The average, standard deviation and 
standard error were calculated for each ISR time point. 
 
3.2.2 Hepatic Cell Lines 
 
3.2.2.1 rHepG2 Cells 
Cells were plated on day -1 at a concentration of 1x106 cells per well of a 6 well 
plate containing 2mL culture medium.  Cells were transduced in culture medium on day 
0 with either AdG3-2xfur (Multiplicity of infection (MOI) =1), AdG3-Track (MOI=0.17) or 
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AdG3-InsTail (MOI=0.25).  The MOI was calculated by dividing the plaque forming units 
(PFU) of each virus by the average number of cells per well.  The PFU value for each 
virus was experimentally determined by the laboratory of Dr. Peter Thulé.  Medium was 
changed on day 1 to basal medium.  Samples were taken at 0, 12 and 24 hours after 
medium change on day 1.   
On day 2 (24 hours after 0 hour sample), the medium was changed to either 
glucose only medium (glucose), cocktail, or basal medium (for control wells). Samples 
were taken at 24, 26, 28, 36 and 48 hours.   
Insulin accumulation was calculated for each of the time points.  It was assumed 
that the wells contained 0mM of insulin immediately after a change in medium.  Four 
independent experiments (each containing 2 sampled wells) were averaged and the 
standard deviation and standard error between the experiments were evaluated.  A 
Grubb’s T test was performed to determine the existence of outliers.  The 12/08/07 
experiment was not performed on the HepG2 cells, therefore it was not necessary to 
remove this test from the calculations and only analyze three independent experiments.  
A complete listing of data points may be found in Appendix A. 
Insulin secretion rate (ISR) was calculated as seen with the GLUTag-INS cells on 
the previous page. 
 
3.2.2.2 rH4IIE Cells 
Cells were plated on day -1 at a concentration of 0.5x106 cells per well of a 6 well 
plate containing 2mL culture medium.  Cells were transduced in culture medium on day 
0 with either AdG3-2xfur (MOI=4), AdG3-Track (MOI=1) or AdG3-InsTail (MOI=4).  The 
MOI was calculated as described in section 3.2.2.1 for rHepG2 cells.  Media in all wells 
were changed on day 1 to BASAL medium.  Samples were taken at 0, 12 and 24 hours 
after medium change on day 1.   
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On day 2, the medium was changed to glucose, cocktail or basal (for control 
wells) medium. Samples were taken at 24, 26, 28, 36 and 48 hours (after medium 
change on day 1).   
Insulin accumulation was calculated for each of the time points as seen with the 
rHepG2 and GLUTag-INS cell lines.  It was assumed that the wells contained 0mM of 
insulin immediately after a change in medium.  The four independent experiments (each 
containing 2 sampled wells) were averaged and the standard deviation and standard 
error between the experiments were evaluated.  A Grubb’s T test was performed to 
determine the existence of outliers.  The calculations showed that the experiment from 
12/08/07 was an outlier for almost every well.  Because of this statistical determination, 
the entire experiment was removed from the calculations and only three independent 
experiments were analyzed.  A complete listing of the data points may be found in 
Appendix A.   
Insulin secretion rate (ISR) was calculated as seen with the GLUTag-INS cells 
and rHepG2 cells on the previous pages. 
 
3.3 Analytical Techniques 
 Insulin concentrations were measured using either a human insulin specific 
radioimmunoassay (RIA) kit (Linco Research, St. Charles, MO) or ultra sensitive human 
insulin RIA kit (Linco Research) depending on the insulin concentration in the sample.  
Radioactivity was determined using an Auto-Gamma Counting System, Cobra II 
(Packard, Meriden, CT).   
Light and fluorescent microscopy pictures were captured using Olympus IX71 
microscope and DP software (Olympus, Japan).   
Cell number was measured daily using parallel wells for each vector type.  The 
counted wells were exposed to the glucose only stimulation protocol.  The viable cell 
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number was measured using 0.4% trypan blue (Sigma) at a ratio of 100μL cell 
suspension to 100 μL trypan blue.   
Several two-way ANOVAs followed by the Tukey’s post-hoc analysis were 
performed to determine the statistical significance of the data.  A Grubb’s T test was 
performed to determine if outliers could be removed from the calculations.   
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CHAPTER 4 
RESULTS 
 
This chapter describes results on the insulin secretion kinetics of recombinant 
hepatic and intestinal cell lines and the potential for combining these two cell types to 
reproduce the glucose responsive insulin secretion kinetics of a normal, functioning 
beta-cell.  The adenovirus vectors containing glucose responsive promoters and furin 
compatible insulin were obtained from the laboratory of Dr. Peter Thulé.  The stably 
transfected GLUTag-INS cells were developed in the Sambanis lab by Heather Bara.   
For the data in this chapter, two hepatic cell lines were transduced with these 
viruses and subjected to secretion studies to analyze the insulin secretion kinetics in 
response to glucose only or a cocktail of nutrient secretagogues [meat hydrolysate (MH) 
and glucose].  With GLUTag-INS cells, the secretion studies were performed to analyze 
the insulin secretion kinetics of these cells in response to a stimulus of MH only or a 
cocktail of MH and glucose.   
 
4.1 Stimulation Response of Recombinant H4IIE Cells 
 The rH4IIE cells were transduced with either AdG3-2xfur (MOI = 4), AdG3-Track 
(MOI = 1) or AdG3-InsTail (MOI = 4).   Following transduction, cells were maintained in 
basal medium for 24 hours and then changed to either stimulation medium or fresh basal 
medium for control cells for an additional 24 hours (48 hours total).  Stimulation media 
consisted of  either 20mM glucose or a cocktail of 20mM glucose and 2% MH.   
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4.1.1 Stimulation Response of H4IIE Cells Transduced with AdG3-2xfur 
 At the 48 hour time point (24 hours of insulin accumulation), the H4IIE cells 
transduced with AdG3-2xfur and stimulated by the cocktail medium exhibited a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (p ≤ 0.001) (n = 3) and the control cells (p ≤ 0.001) (n = 3) (Figure 8 ).  The 
cocktail stimulated cells exhibited a significant increase in accumulated insulin over time 
(p < 0.05).  The glucose only and control cells did not experience a statistically 
significant increase in insulin secretion over time (p >  0.05). 
 
 
Figure 8: Insulin accumulation of H4IIE cells transduced with AdG3-2xfur.  The 
H4IIE cells were plated in 6 well plates, transduced with AdG3-2xfur (MOI=4), and were 
exposed to basal medium for 24 hours then stimulated with either basal medium (for 
control cells), glucose only medium, or a cocktail of glucose and meat hydrolysate 
medium.  Insulin accumulation was measured over time.  The cocktail stimulated cells 
also exhibited a significant increase in insulin accumulation over time (p < 0.05) when 
comparing 48 to 28 and 48 to 36 hours, but not when comparing 36 to 28 hours.  The 
cells stimulated by only glucose and the control cells did not exhibit a significant increase 
in insulin accumulation over time (p > 0.05) when comparing 48 to 36, 48 to 28 or 36 to 
28.  *p ≤ 0.001; bars are ± SE; n = 3 for each data point; arrow indicates change in 
medium to stimulation medium. 
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4.1.2 Stimulation Response of H4IIE Cells Transduced with AdG3-Track 
 At the 48 hour time point (24 hours of insulin accumulation), H4IIE cells 
transduced with AdG3-Track and stimulated by the cocktail medium did not exhibit a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (n = 3) and the control cells (n = 3) (Figure 9).  Also, the cells stimulated by 
glucose only medium did not exhibit a significant increase in accumulated insulin 
secretion over the control cells (p>0.05).  The cocktail stimulated cells exhibited a 
significant increase in accumulated insulin over time (p < 0.05).  The cells stimulated by 
glucose only medium did not experience a significant increase in accumulated insulin 
over time (p > 0.05).  The control cells did not exhibit a significant increase in insulin 
secretion over time (p > 0.05) 
 
 
Figure 9: Insulin accumulation of H4IIE cells transduced with AdG3-Track. The 
H4IIE cells were transduced with AdG3-Track (MOI = 1) and were exposed to basal 
medium for 24 hours then stimulated with either basal medium (for control cells), glucose 
only medium, or a cocktail of glucose and meat hydrolysate medium.  The cocktail 
stimulated cells exhibited a significant increase in insulin accumulation over time (p < 
0.05) when comparing 48 to 28 and 48 to 36 hours, but not when comparing 36 to 28.  
The glucose only stimulated cells exhibited a significant increase in insulin secretion 
over time (p < 0.05) when comparing 48 to 28 hours, but not when comparing 48 to 36 
and 36 to 28 (p > 0.05).   The control cells did not exhibit a significant increase in insulin 
secretion over time (p > 0.05).  *p ≤ 0.001; bars are ± SE; n = 3 for each data point; 
arrow indicates change in medium to stimulation medium. 
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Fluorescent imaging of the transduced cells showed the high transduction efficiency of 
the AdG3-Track virus.  It appears that almost 100% of the cells were effectively 
transduced. 
 
 
 
Figure 10: Microscope images of H4IIE transduced with AdG3-Track.  The H4IIE 
were transduced in 6 well plates at MOI of 1.  The wells were imaged using a fluorescent 
microscope to compare the same section of the plate.  A) light image of rH4IIE cells B) 
fluorescent image of rH4IIE cells (mag x10) 
 
 
4.1.3 Stimulation Response of H4IIE Cells Transduced with AdG3-InsTail 
 At the 48 hour time point (24 hours of insulin accumulation), H4IIE cells 
transduced with AdG3-InsTail and stimulated by the cocktail medium exhibited a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (p ≤ 0.001) (n = 3) and the control cells (p ≤ 0.001) (n = 3) (Figure 11).  The 
cocktail stimulated cells exhibited a significant increase in accumulated insulin over time 
(p ≤ 0.001).  The cells stimulated by glucose only medium also experienced a significant 
increase in insulin expression over time (p ≤ 0.05).  The AdG3-Ins Tail cells also 
exhibited significantly less insulin secretion after 24 hours of stimulation with cocktail 
medium (1.61 ±  standard deviation of 0.15 μU/105 cells) compared to the AdG3-Track 
A B
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(167.14 ± standard deviation of 85.03 μU/105 cells) and AdG3-2xfur cells (36.04 ±  
standard deviation of 9.90 μU/105 cells).   
 
 
 
Figure 11: Insulin accumulation of H4IIE cells transduced with AdG3-InsTail.  The 
H4IIE cells were plated in 6 well plates, transduced with AdG3-InsTail (MOI = 4), and 
were exposed to basal medium for 24 hours then stimulated with either basal medium 
(for control cells), glucose only medium, or a cocktail of glucose and meat hydrolysate 
medium.  The cocktail stimulated cells exhibited a significant increase in insulin 
accumulation over time (p ≤ 0.001) when comparing 48 to 28 and 48 to 36 hours, but not 
when comparing 36 to 28 The cells stimulated by glucose only medium exhibited a 
significant increase in insulin accumulation over time (p ≤ 0.05) when comparing 48 to 
28 and 48 to 36 hours. The control cells did not experience a significant increase in 
insulin over time when comparing 48 to 28, 48 to 36 or 36 to 28 (p > 0.05).  *p ≤ 0.001; 
bars are ± SE; n = 3 for each data point; arrow indicates change in medium to 
stimulation medium. 
  
 
  
4.2 Stimulation Response of Recombinant HepG2 Cells 
 The HepG2 cells were transduced with either AdG3-2xfur (MOI = 1), AdG3-Track 
(MOI = 0.17) or AdG3-InsTail (MOI = 0.25).   The cells were maintained in basal medium 
for 24 hours and then changed to stimulation medium for an additional 24 hours (48 
hours total).  Stimulation was either 20mM glucose or a cocktail of 20mM glucose and 
2% MH.   
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4.2.1 Response of HepG2 Cells Transduced with AdG3-2xfur 
 At the 48 hour time point (24 hours of insulin accumulation), the HepG2 cells 
transduced with AdG3-2xfur and stimulated by the cocktail medium exhibited a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (p ≤ 0.001) (n = 3) and the control cells (p ≤ 0.001) (n = 3) (Figure 12).  The 
cocktail stimulated cells exhibited a significant increase in accumulated insulin over time 
(p ≤ 0.001).   
 
 
 
 
Figure 12: Insulin accumulation in HepG2 cells transduced with AdG3-2xfur. The 
HepG2 cells were transduced with AdG3-2xfur (MOI = 1) and exposed to basal medium 
for 24 hours then stimulated with either basal medium (for control cells), glucose only 
medium, or a cocktail of glucose and meat hydrolysate medium.  The cocktail stimulated 
cells exhibited a significant increase in insulin accumulation over time (p ≤ 0.001) when 
comparing 48 to 28 and 48 to 36 hours, but not when comparing 36 to 28 (p > 0.05). The 
cells stimulated by only glucose medium did not experience a significant increase in 
insulin over time when comparing 48 to 28, 48 to 36 and 36 to 28 (p > 0.05).  The control 
cells did not experience a significant increase in insulin over time when comparing 48 to 
28, 48 to 36 and 36 to 28 (p > 0.05).  *p ≤ 0.001; bars are ± SE; n = 3 for each data 
point; arrow indicates change in medium to stimulation medium. 
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4.2.2 Response of HepG2 Cells Transduced with AdG3-Track 
 At the 48 hour time point (24 hours of insulin accumulation), HepG2 cells 
transduced with AdG3-Track and stimulated by the cocktail medium exhibited a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (p ≤ 0.001) (n = 3) and the control cells (p ≤ 0.001) (n = 3) (Figure 13).  The 
cocktail and glucose only stimulated cells exhibited a significant increase in accumulated 
insulin over time (p ≤ 0.05).   
 
 
Figure 13: Insulin accumulation in HepG2 cells transduced with AdG3-Track.  The 
HepG2 cells were transduced with AdG3-Track (MOI = 0.17) and exposed to basal 
medium for 24 hours then stimulated with either basal medium (for control cells), glucose 
only medium, or a cocktail of glucose and meat hydrolysate medium.  Insulin 
accumulation was measured over time.  The cocktail stimulated cells exhibited a 
significant increase in insulin accumulation over time (p ≤ 0.001) when comparing 48 to 
26, 48 to 28, and 48 to 36 hours, but not when comparing 36 to 28 did not experience a 
significant increase in insulin over time when comparing 48 to 28, 48 to 36 and 36 to 28 
(p > 0.05). The cells stimulated by only glucose medium experienced a significant 
increase in insulin over time (p ≤ 0.05) when comparing 48 to 28 and 48 to 36 hours, but 
not when comparing 36 to 28 (p > 0.05).  The control cells experienced a significant 
increase in insulin secretion over time (p ≤ 0.05) when comparing 48 to 28, and 48 to 36 
hours, but not when comparing 36 to 28 (p > 0.05).  *p ≤ 0.001; bars are ± SE; n = 3 for 
each data point; arrow indicates change in medium to stimulation medium. 
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Fluorescent imaging of the HepG2 cells transduced with AdG3-Track demonstrated the 
high transduction efficiency of the virus.  It appears that almost 100% of the cells were 
transduced by the virus (Figure 14). 
 
 
Figure 14: Microscope images of HepG2 Cells transduced with AdG3-Track.  The 
HepG2 cells were transduced with AdG3-Track in 6 well plates at MOI of 0.17.  The 
wells were imaged using a fluorescent microscope to compare the same section of the 
plate.  A) light image of rHepG2 cells B) fluorescent image of rHepG2 cells  
(mag x10) 
   
4.2.3 Response of HepG2 Cells Transduced with AdG3-InsTail 
 At the 48 hour time point (24 hours of insulin accumulation), HepG2 cells 
transduced with AdG3-InsTail and stimulated by the cocktail medium exhibited a 
significant increase in accumulated insulin over the cells stimulated by only glucose 
medium (p ≤ 0.001) (n = 3) and the control cells (p ≤ 0.001) (n = 3) (Figure 15).  The 
cocktail stimulated cells exhibited a significant increase in accumulated insulin over time 
(p ≤ 0.001).  The glucose only stimulated cells and control cells exhibited an increase in 
insulin secretion with time which was less pronounced than the cocktail stimulated cells.  
The AdG3-Ins Tail cells also exhibited significantly less insulin secretion after 24 hours 
of stimulation with cocktail medium (2.88 ±  standard deviation of 0.52 μU/105 cells) 
A B
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compared to the AdG3-Track (119.36 ± standard deviation of 24.88 μU/105 cells) and 
AdG3-2xfur cells (180.33 ± standard deviation of 26.84 μU/105 cells).   
 
 
Figure 15: Insulin accumulation in HepG2 cells transduced with AdG3-InsTail.  The 
HepG2 cells were transduced with AdG3-InsTail (MOI = 0.25) and exposed to basal 
medium for 24 hours then stimulated with either basal medium (for control cells), glucose 
only medium, or a cocktail of glucose and meat hydrolysate medium.  Insulin 
accumulation was measured over time.  The cocktail stimulated cells exhibited a 
significant increase in insulin accumulation over time (p ≤ 0.001) when comparing 48 to 
26, 48 to 28, and 48 to 36 hours, but not when comparing 36 to 28 (p > 0.05).  The cells 
stimulated by only glucose medium experienced a significant increase in insulin over 
time (p ≤ 0.05) when comparing 48 to 28 hours, but not when comparing 36 to 28 (p > 
0.05).  The control cells experienced a significant increase in insulin secretion when 
comparing 48 to 28, but not when comparing 48 to 36 and 36 to 28 (p > 0.05).  *p ≤ 
0.001; bars are ± SE; n = 3 for each data point; arrow indicates change in medium to 
stimulation medium. 
 
 
4.3 Stimulation Response of GLUTag-INS Cells 
 GLUTag-INS cells were stably transfected with the vector shown in Figure 7 and 
stimulated with either 2% MH alone (MH) or a cocktail of 20mM glucose and 2% MH.   
The cells were maintained in basal medium for 24 hours and then changed to stimulation 
medium for an additional 24 hours (48 hours total).   
 At the 48 hour time point (24 hours of insulin accumulation), GLUTag-INS 
stimulated by the cocktail medium exhibited a significant increase in accumulated insulin 
over the control cells (p ≤ 0.05) (n = 3) (Figure 16).  The GLUTag-INS cells stimulated by 
MH only (MH) also exhibited a significant increase in accumulated insulin over the 
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control cells (p ≤ 0.05).  There was no difference between MH only stimulated cells and 
cocktail stimulated at 48 hours.   
The cocktail stimulated GLUTag-INS cells exhibited a significant increase in 
accumulated insulin over time (p ≤ 0.001).  The MH stimulated GLUTag-INS cells also 
exhibited a significant increase in accumulated insulin over time (p ≤ 0.001)   
 
 
Figure 16: Insulin accumulation in GLUTag-INS cells.  GLUTag-INS cells were stably 
transfected and exposed to basal medium for 24 hours then stimulated with either basal 
medium (for control cells), meat hydrolysate (MH) only medium, or a cocktail of glucose 
and meat hydrolysate medium.  Insulin accumulation was measured over time.  The 
cocktail stimulated cells exhibited a significant increase in insulin accumulation over time 
(p ≤ 0.05) when comparing 48 to 28, 48 to 36 and 36 to 26 hours.  The cells stimulated 
by only MH medium exhibited a significant increase in insulin accumulation over time (p 
≤ 0.05) when comparing 48 to 26, 48 to 28 and 48 to 36 hours, but not when comparing 
36 to 28 (p > 0.05). The control cells exhibited a significant increase in insulin 
accumulation over time (p ≤ 0.05) when comparing 48 to 26 hours and 48 to 36, but not 
when comparing 36 to 28 (p > 0.05).  † p ≤ 0.05; bars are ± SE; n = 3 for each data 
point; arrow indicates change to stimulation medium. 
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CHAPTER 5 
 
DISCUSSION 
 
 
5.1 Comparison of Adenovirus Vectors within H4IIE and HepG2 Cells 
Cell sourcing is a critical issue in creating a cell-based therapy for IDD.  Non-beta 
cells such as hepatic and intestinal cells offer potentially autologous cell sources.  It has 
been shown in this paper that recombinant hepatic cells will respond to a glucose 
stimulation, but exhibit sluggish kinetics.  These cells must be combined with a 
complimentary cell type, such as recombinant EE cells, which provide the initial burst of 
insulin from secretory granules.   
Three adenoviral vectors were analyzed in HepG2 and H4IIE hepatic cell lines.  
The three vectors exhibited various responses to stimulation. This was demonstrated 
when recombinant hepatic cells transduced with AdG3-2xfur, AdG3-Track, and AdG3-
InsTail were stimulated with the cocktail medium.  The data reported in Figures 8, 9, 11, 
12, 13, and 15 have been re-graphed to compare the three vectors in H4IIE (Figure 17A) 
and HepG2 (Figure 17B) cells under the same stimulation condition.  
 At the 48 hour time point (24 hours of induced insulin accumulation), the AdG3-
Track vector secreted significantly more insulin compared to the AdG3-2xfur (p ≤ 0.001) 
and AdG3-InsTail (p ≤ 0.001) vectors in both H4IIE and HepG2 cells (Figure 17).  The 
H4IIE and HepG2 cells transduced with AdG3-2xfur also secreted significantly more 
insulin than AdG3-InsTail (p ≤ 0.001).    
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Figure 17: Comparison of vectors stimulated with cocktail medium.  A) H4IIE Cells 
transduced with either AdG3-2xfur, AdG3-Track or AdG3-InsTail.  B) HepG2 Cells 
transduced with either AdG3-2xfur, AdG3-Track or AdG3-InsTail. The HepG2 and H4IIE 
cells transduced with AdG3-Track secreted significantly more insulin than AdG3-2xfur 
and AdG3-InsTail.  Also AdG3-2xfur secreted significantly more insulin than AdG3-
InsTail. *p ≤ 0.001; values are ± SE; n = 3 for each data point.   
 
 
After stimulation with cocktail medium, AdG3-InsTail secreted less insulin likely 
due to the expedited decay of the engineered PPI mRNA allowing for faster elimination 
of the mRNA.  This engineered PPI vector also required an MOI value 4 fold more than 
AdG3-Track in rH4IIE cells.  Despite its lower MOI, AdG3-Track in H4IIE cells exhibited 
approximately 4.6 fold more insulin secretion than AdG3-2xfur and approximately 103.8 
fold more than AdG3-InsTail.  The HepG2 cells were transduced with a 6 fold higher 
MOI of AdG3-2xfur and 4 fold higher MOI of AdG3-InsTail when comparing to AdG3-
Track, however, AdG3-Track resulted in higher insulin secretion (2.9 fold more insulin 
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secretion with AdG3-Track versus AdG3-2xfur and 181.3 fold more with AdG3-Track 
versus AdG3-InsTail).  This difference is more pronounced than that of primary cells in 
vivo which required 1.75 fold more AdG3-InsTail than AdG3-2xfur to restore 
normoglycemia in mice (unpublished work by Thule et al).  Therefore, indicating that 
AdG3-2xfur secretes 1.75 fold more insulin than AdG3-InsTail and the cell lines 
exhibited a larger loss of expression than primary cells.   
The H4IIE and HepG2 cells transduced with AdG3-Track experienced almost 
100% transduction efficiency and GFP expression with MOI values of 1 and 0.17, 
respectively, when viewed with a fluorescent microscope (Figure 10 and Figure 14).  
Despite a low MOI value of less than 1 viral particle per cell in HepG2 cells, almost 
100% of the cells were expressing GFP.  The calculation for MOI is based on the 
measuring plaque forming units (PFU) and the number of cells per well.  The PFU value 
is not an absolute measure of virus transduction efficiency in cells.  Transduction 
efficiency is dependent on several factors including the cell type, confluency of plated 
cells and medium conditions.  The PFU values for the vectors used here  were 
determined using non-liver cells (Communication with Dr. Peter Thulé).  Therefore, it is 
possible that the original PFU values were not completely accurate before performing 
the experiments consequently affecting the calculations for the MOI value.  Comparison 
of transduction efficiency of AdG3-Track to the transduction efficiency of AdG3-2xfur and 
AdG3-InsTail using microscopy is not possible because the two latter vectors do not 
express fluorescence.   
Assuming the calculations for PFU were accurate, composition of the vectors 
was evaluated to determine is difference there may explain how AdG3-Track secretes a 
larger amount of insulin and requires a lower MOI than AdG3-InsTail and AdG3-2xfur.  
The difference between AdG3-Track and AdG3-2xfur is the addition of the downstream 
CMV promoter and GFP.  The CMV incorporated contained an immediate-early 
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promoter enhancer, which is capable of bidirectional transcription allowing the 
transcription of genes both upstream and downstream from the promoter (Grzimek, 
Podlech et al. 1999; Simon, Kuhnapfel et al. 2007).  This phenomenon suggests that 
AdG3-Track secreted more insulin possibly because the CMV promoter stimulated gene 
transcription of the upstream PPI gene.   
 
 
5.2 Effects of Secretagogues on rH4IIE, rHepG2 and GLUTag-INS cells 
 
5.2.1 Effect of Meat Hydrolysate (MH) 
The release of insulin from GLUTag-INS cells is related to the release kinetics of 
GLP-1 due to their assumed co-localization in secretory granules.  To further understand 
the insulin secretion from these cells, we must have a better understanding of the GLP-1 
secretion.   
GLP-1 secretion is stimulated by various carbohydrates, fats and proteins 
(Reimann, Ward et al. 2006). The digestion of proteins in the stomach and intestine 
yields mainly amino acids and oligopeptides (Cordier-Bussat, Bernard et al. 1997).  
Peptones stimulate the release of secretory granules containing GLP-1. The 
mechanisms by which these stimulate GLP-1 secretion is poorly characterized (Reimer, 
Darimont et al. 2001).  One type of protein hydrolysate or peptone, MH, has been shown 
to stimulate the release of GLP-1 from L cells (Cordier-Bussat, Bernard et al. 1998; 
Reimer, Darimont et al. 2001; Reimann, Ward et al. 2006; Reimer 2006).   
It has been reported that peptones also stimulate proglucagon gene transcription 
in colonic proglucagon-expressing cell lines such as GLUTag and STC-1 (Cordier-
Bussat, Bernard et al. 1998; Reimann, Ward et al. 2006).  Peptones directly increase the 
level of  glucagon mRNA though peptone-responsive elements in the promoter (Cordier-
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Bussat, Bernard et al. 1997).  The posttranslational processing of the proglucagon 
peptide results in GLP-1.   
The increase in proglucagon gene transcription may also explain the effect of MH 
on hepatic cells.  The mechanism for induction of proglucagon gene transcription is 
through a cascade of events which raise intracellular cAMP levels (Gevrey, Malapel et 
al. 2004).  This is coupled with membrane depolarization and increased intracellular 
calcium which enhance GLP-1 secretion (Reimann, Ward et al. 2006).  Though the 
hepatic cells do not express proglucagon, the peptones may have a stimulation effect on 
the GlRE3 promoter used in the rHepG2 and rH4IIE cells.  
It is important to note that MH was shown by Heather Bara to inhibit glucose 
induced insulin secretion from primary rat hepatocytes (unpublished data).  This 
phenomenon contrasts the findings in this thesis which showed that MH potentiated 
glucose induced insulin secretion in hepatic cell lines.  The reasoning for this 
phenomenon is unclear.  This could possibly be explained with the differences between 
primary and immortalized cell lines.  It has been reported that immortalized cell lines 
may experience alterations in glucose sensitivity as seen in some insulinoma cell lines 
(Reimann and Gribble 2002).    
 
5.2.2 Effect of Glucose 
The addition of glucose to stimulate GLUTag-INS cells did not increase the 
insulin secretion from the cells over stimulation with only MH (Figure 16).  These cells 
are not responsive to glucose at this high (20mM) concentration.  This is supported by 
the work of Reimann and Gribble who analyzed GLUTag cells under increasing 
concentrations of glucose (2002).  It was determined that an increase in the glucose 
concentration from 0mM to 0.5 mM of glucose resulted in an increase in GLP-1 
secretion, but there was no response to increasing concentrations of glucose  from 5mM 
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to 25mM (Reimann and Gribble 2002; Gribble, Williams et al. 2003).  This was also seen 
in primary L cell cultures by Damholt et al (1998).  The cell cultures were under 2mM 
glucose during the basal period which was calculated to be reduced by the cells to 1.5 
mM over 24 hours (using a glucose consumption rate of 7.9 x10-5 mmol/hr-106 cells).    
Therefore, the cells consistently experienced over 0.5mM of glucose and were not 
starved before stimulation.  Starving of the cells before stimulation may provide an 
exaggerated increase in insulin secretion after stimulation, which may be a metabolic 
effect and not due to glucose acting as a secretion agonist.  This phenomenon is seen in 
beta-cells in a buffer solution, which experience lower insulin secretion both basally and 
after glucose stimulation when compared to cells in cell culture medium (Papas and 
Jarema 1998).   
 
5.3 Comparison of ISR Between Hepatic and Intestinal cells  
 In order to compare the kinetics of insulin release in the recombinant hepatic 
and intestinal cell lines, the previous data were re-analyzed to calculate insulin secretion 
rate (ISR).  It was determined that recombinant hepatic cells transduced with AdG3-
InsTail did not secrete enough insulin to be a viable option for combining with the 
GLUTag-INS cells.  The hepatic cells transduced with AdG3-2xfur and AdG3-Track were 
graphed together to demonstrate the differences in insulin secretion rates.   
 The GLUTag-INS cells experienced approximately a 2 fold increase in ISR 
between 26 and 28 hours while the rH4IIE cells transduced with AdG3-2xfur 
experienced only a 1.25 fold increase (Figure 18).  The ISR demonstrates that GLUTag-
INS cells respond with faster kinetics, which simulates the first phase of insulin secretion 
from the beta-cells.  This burst of insulin release is due to the presence of secretory 
granules which are released upon stimulation.  The ISR from rH4IIE cells transduced by 
AdG3-2xfur responded with slower kinetics simulating the second phase of insulin 
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secretion from beta-cells.  This slower response is due to the lack of secretory granules 
and illustrates the slower kinetics of transcriptional regulation of insulin release.  
Combining recombinant hepatic and intestinal cell lines further illustrates their varying 
insulin secretion responses to stimulation.  The burst of insulin released from the EE 
cells should quickly lower the blood glucose levels back to normal.  The recombinant 
hepatic cells should maintain this lowered blood glucose level through its sustained 
insulin release.  Similar trends were seen with HepG2 cells (Figure 19) 
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Figure 18: ISR for H4IIE transduced with AdG3-2xfur and GLUTag-INS cells.   
A) The data presented earlier have been re-analyzed to determine the insulin secretion 
rate (ISR) of H4IIE cells transduced with AdG3-2xfur and GLUTag-INS cells when 
stimulated with cocktail medium.  B) The combined ISR values of the rH4IIE cells and 
GLUTag-INS cells were derived from the ISR values in Graph A and added at a cell ratio 
of 1:1 rH4IIE to GLUTag-INS to determine the total ISR.  It was assumed that the two 
cell types had no interactions and that the total amount of insulin secreted would be the 
sum of the insulin secreted by each cell population.  *p ≤ 0.001; values are ± SE; n = 3 
for each data point.   
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Figure 19: ISR for HepG2 transduced with AdG3-2xfur and GLUTag-INS cells.   
A) The data presented earlier have been re-analyzed to determine the insulin secretion 
rate (ISR) of HepG2 cells transduced with AdG3-2xfur and GLUTag-INS cells when 
stimulated at 24 hours with cocktail medium.  B) The combined ISR values of the 
rHepG2 and GLUTag-INS cells were derived from the ISR values in Graph A and added 
at a cell ratio of 1:3 rH4IIE to GLUTag-INS to determine the total ISR.  It was assumed 
that the two cell types had no interactions and that the total amount of insulin secreted 
would be the sum of the insulin secreted by each cell population. *p ≤ 0.001; values are 
± SE; n = 3 for each data point.   
 
 
 When H4IIE and HepG2 cells were transduced with AdG3-Track, they released 
significantly more insulin than GLUTag-INS cells.  The cell number for the combination 
of cells was adjusted to compensate for the differences in the amounts of insulin 
accumulation.  The AdG3-Track transduced H4IIE cells secreted significantly more 
insulin than those transduced with AdG3-2xfur (Figure 20).  In order to combine the 
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H4IIE cells transduced with AdG3-Track with the GLUTag-INS cells, a ratio of 9 
GLUTag-INS cells to 1 H4IIE cell transduced with AdG3-Track were combined.  After 
adjusting the ratio for the number of cells, the two distinct phases seen by the different 
cell types was realized.  As seen earlier, GLUTag-INS cells experienced a 2 fold 
increase in ISR between 26 and 28 hours which decreased after 36 hours.  The H4IIE 
cells transduced with AdG3-Track experienced a slower and more sustained increase in 
insulin secretion which was maintained through 48 hours.  Similar trends were seen with 
HepG2 cells transduced with AdG3-2xfur (Figure 21).   
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Figure 20: ISR for H4IIE transduced with AdG3-Track and GLUTag-INS cells.   
A) The data presented earlier have been re-analyzed to determine the insulin secretion 
rate (ISR) of H4IIE cells transduced with AdG3-Track and GLUTag-INS cells when 
stimulated at 24 hours with cocktail medium.  B) The combined ISR of the rH4IIE cells 
and GLUTag-INS cells were derived from the ISR values in Graph A and added at a cell 
ratio of 1:9 rH4IIE to GLUTag-INS to determine the total ISR.  It was assumed that the 
two cell types had no interactions and that the total amount of insulin secreted would be 
the sum of the insulin secreted by each cell population.  *p ≤ 0.001; values are ± SE; n = 
3 for each data point.   
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Figure 21: ISR for HepG2 transduced with AdG3-Track and GLUTag-INS cells.   
A) The data presented earlier have been re-analyzed to determine the insulin secretion 
rate (ISR) of HepG2 cells transduced with AdG3-Track and GLUTag-INS cells when 
stimulated at 24 hours with cocktail medium. B) The combined ISR values of the rHepG2 
cells and GLUTag-INS cells were derived from the ISR values in Graph A and added at 
a cell ratio of 1:8 rHepgG2 to GLUTag-INS to determine the total ISR.  It was assumed 
that the two cell types had no interactions and that the total amount of insulin secreted 
would be the sum of the two individual cells types.*p ≤ 0.001; values are ± SE; n = 3 for 
each data point. 
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CHAPTER 6 
CONCLUSIONS 
 
6.1 Conclusions 
A combination of recombinant hepatic and intestinal cells offers a promising 
approach for the treatment of diabetes using engineered non-beta cells.  We have 
described the kinetics of insulin secretion from two recombinant hepatic cell lines 
transduced with one of three adenovirus vectors, along with a recombinant intestinal cell 
line stably transfected with an insulin transgene.  Assuming only an additive effect, the 
combination of these cells may better approximate the biphasic insulin secretion 
dynamics of normal functioning beta-cells than either cell type alone.   
 
6.2 Future Recommendations 
 The experiments presented in this thesis characterized the kinetics of secretion 
from recombinant hepatic and enteroendocrine L cell lines; the secretion rates were 
added up to see how a (otherwise non-interacting) co-culture would secrete.  This 
approach may potentially develop into a treatment for diabetes based on autologous 
cells as a personalized therapy.  The experiments for this thesis were performed using 
continuous cell lines.  To delve further into this treatment option, the intestinal and 
hepatic cell lines should be combined in a co-culture in vitro allowing communication via 
medium between the two cell types.  The same experiment would be performed in vitro 
with primary cells; testing their ability to reproduce the secretion dynamics.  At this time, 
a protocol for the isolation of primary L cells has not been established in our lab and it 
would require further investigation to determine this method.  Once the insulin secretion 
50 
dynamics have been confirmed in vitro, the experiments should be performed in vivo in 
small animals such as mice.   
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APPENDIX A 
FULL DATA SET 
Cell Type Gene STIM Time 
Expt 1 Expt 2 Expt 3 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
H4IIE AdG3-2xfur CONTROL 
0 0.12 0.09 0.12 
12 3.04 2.11 1.63 
24- 1.62 3.28 3.57 
24+ 0.08 0.11 0.17 
26 0.41 0.55 0.50 
28 0.70 1.15 1.14 
36 1.95 3.30 2.83 
48 3.00 9.29 15.87 
              
H4IIE AdG3-2xfur GLUCOSE 
0 0.11 0.08 0.12 
12 3.59 2.68 1.90 
24- 0.41 3.14 2.90 
24+ 2.99 0.14 0.21 
26 0.77 0.63 0.39 
28 1.13 0.89 0.77 
36 3.35 2.65 2.22 
48 4.51 14.64 15.25 
              
H4IIE AdG3-2xfur COCKTAIL 
0 0.67 0.12 0.26 
12 3.34 2.77 1.94 
24- 2.51 7.03 3.18 
24+ 0.31 0.08 0.33 
26 0.62 0.45 0.56 
28 0.79 0.97 1.08 
36 4.79 4.43 4.12 
48 36.69 18.57 52.85 
              
H4IIE AdG3Track CONTROL 
0 0.52 0.25 0.87 
12 20.02 12.00 2.76 
24- 21.70 41.69 5.59 
24+ 0.39 0.27 1.20 
26 3.32 1.96 1.53 
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Cell Type Gene STIM Time 
Expt 1 Expt 2 Expt 3 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
28 9.20 7.93 2.60 
36 50.61 52.82 37.25 
48 61.83 198.33 40.40 
              
H4IIE AdG3Track GLUCOSE 
0 0.53 0.46 0.86 
12 15.77 14.37 2.87 
24- 24.90 75.69 4.63 
24+ 0.45 0.70 0.90 
26 2.91 2.92 1.41 
28 10.79 12.57 2.35 
36 53.60 34.49 12.03 
48 73.12 207.33 53.83 
              
H4IIE AdG3Track COCKTAIL 
0 0.57 0.42 1.08 
12 20.68 12.17 3.33 
24- 24.84 42.80 6.05 
24+ 0.40 0.45 0.88 
26 2.70 3.33 1.99 
28 12.77 12.59 2.84 
36 48.99 83.49 11.06 
48 107.31 334.92 59.19 
              
H4IIE AdG3InsTail CONTROL 
0 0.12 0.09 0.19 
12 0.29 0.12 0.23 
24- 0.15 0.21 0.24 
24+ 0.24 0.06 0.12 
26 0.12 0.10 0.15 
28 0.16 0.08 0.20 
36 0.23 0.14 0.19 
48 0.22 0.37 0.76 
              
H4IIE AdG3InsTail GLUCOSE 
0 0.12 0.11 0.16 
12 0.30 0.13 0.20 
24- 0.15 0.20 0.22 
24+ 0.62 0.06 0.11 
26 0.18 0.08 0.14 
28 0.17 0.08 0.15 
53 
Cell Type Gene STIM Time 
Expt 1 Expt 2 Expt 3 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
36 0.33 0.16 0.26 
48 0.29 0.59 1.02 
              
H4IIE AdG3InsTail COCKTAIL 
0 0.12 0.10 0.16 
12 0.34 0.18 0.19 
24- 0.14 0.40 0.23 
24+ 0.28 0.06 0.13 
26 0.12 0.08 0.13 
28 0.14 0.09 0.14 
36 0.26 0.17 0.23 
48 1.79 1.72 1.31 
              
GLUTag-
INS stable CONTROL 
0 0.57 1.09 0.98 
12 3.17 2.66 1.59 
24- 3.11 6.93 4.43 
24+ 0.23 0.37 0.41 
26 0.40 0.56 0.54 
28 0.87 0.93 0.74 
36 0.85 2.72 1.14 
48 7.01 10.41 26.75 
              
GLUTag-
INS stable GLUCOSE 
0 0.47 0.76 0.84 
12 4.08 3.26 1.53 
24- 4.49 7.67 3.29 
24+ 0.30 0.38 0.74 
26 1.16 0.85 0.53 
28 2.35 1.28 1.27 
36 7.29 4.08 3.74 
48 16.58 22.79 52.65 
              
GLUTag-
INS stable COCKTAIL 
0 0.52 0.77 3.01 
12 3.98 2.78 1.70 
24- 3.44 7.37 5.30 
24+ 0.20 0.48 0.75 
26 1.04 1.33 0.88 
28 2.26 2.18 2.07 
36 7.70 8.04 4.90 
48 15.83 39.97 45.71 
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Cell Type Gene STIM Time 
Expt 1 Expt 2 Expt 3 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
HepG2 AdG3-2xfur CONTROL 
0 1.49 3.03 0.74 
12 6.54 4.11 15.74 
24- 10.24 9.35 51.56 
24+ 1.13 1.02 1.59 
26 2.88 2.12 3.77 
28 3.71 2.68 9.30 
36 14.12 5.84 34.83 
48 84.86 25.79 41.52 
              
HepG2 AdG3-2xfur GLUCOSE 
0 1.70 4.56 1.78 
12 6.68 3.15 15.92 
24- 5.76 11.93 47.05 
24+ 7.53 1.05 0.94 
26 2.97 2.01 3.77 
28 4.30 3.06 6.42 
36 17.21 5.74 37.05 
48 95.34 24.84 30.91 
              
HepG2 AdG3-2xfur COCKTAIL 
0 2.06 3.59 0.69 
12 5.72 5.47 16.44 
24- 19.53 17.09 53.61 
24+ 2.94 1.62 0.97 
26 2.96 3.29 4.98 
28 4.06 6.57 11.66 
36 24.38 16.16 69.19 
48 221.56 189.48 129.94 
              
HepG2 AdG3Track CONTROL 
0 1.51 1.48 3.63 
12 10.40 26.87 21.69 
24- 37.64 65.42 87.58 
24+ 1.48 1.85 0.54 
26 4.29 3.09 5.26 
28 7.11 29.47 18.60 
36 25.61 42.18 61.47 
48 233.50 84.89 150.81 
              
HepG2 AdG3Track GLUCOSE 
0 1.30 1.74 1.11 
12 9.90 23.29 33.94 
24- 37.05 47.59 86.71 
24+ 1.15 1.71 0.74 
55 
Cell Type Gene STIM Time 
Expt 1 Expt 2 Expt 3 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
Average 
cumulative 
μU/10^5 
cells 
26 3.74 2.94 4.21 
28 6.60 9.13 13.48 
36 24.82 22.21 81.70 
48 155.45 71.66 130.98 
              
HepG2 AdG3Track COCKTAIL 
0 1.33 4.24 1.23 
12 8.81 30.46 27.56 
24- 36.02 51.66 90.03 
24+ 1.06 1.62 1.44 
26 4.36 3.29 7.61 
28 8.00 6.57 22.93 
36 87.88 72.17 158.59 
48 745.40 293.22 528.07 
              
HepG2 AdG3InsTail CONTROL 
0 0.27 0.49 0.12 
12 0.34 0.26 0.27 
24- 0.23 0.51 0.38 
24+ 0.25 0.10 0.11 
26 0.24 0.13 0.16 
28 0.25 0.15 0.21 
36 0.44 0.31 2.45 
48 0.91 0.54 1.61 
              
HepG2 AdG3InsTail GLUCOSE 
0 0.26 0.40 0.12 
12 0.37 0.25 0.29 
24- 0.22 0.44 0.65 
24+ 0.20 0.10 0.09 
26 0.20 0.16 0.13 
28 0.21 0.19 0.23 
36 0.48 0.30 1.23 
48 0.94 1.05 0.93 
              
HepG2 AdG3InsTail COCKTAIL 
0 0.29 0.20 0.08 
12 0.58 0.31 0.27 
24- 0.21 0.58 0.51 
24+ 0.30 0.11 0.10 
26 0.23 0.17 0.17 
28 0.24 0.24 0.27 
36 0.64 0.92 1.74 
48 2.48 3.91 2.24 
              
56 
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